The present invention relates to an N-(4-((4-(3-phenylureido)phenyl)sulfonyl)phenyl)benzenesulfonamide in the polymorphic form ω.sup.18.9, characterised by an x-ray powder diffractogram having the Bragg angles (2θ/CuK.sub.α) 10.9, 11.7, 14.6, 15.0, 15.8, 16.6, 17.6, 18.9, 19.4, 20.9, 21.2, 22.0, 23.3, 24.4, 24.7, 26.1, 27.4, 29.4, 34.2,

or in the polymorphic form α.sup.21.2, characterised by an x-ray powder diffractogram having the Bragg angles (2θ/CuK.sub.α) 8.7, 9.8, 10.8, 13.2, 13.9, 14.9, 15.2, 16.0, 17.4, 17.7, 18.7, 20.4, 21.2, 21.6, 22.3, 23.0, 23.3, 23.9, 24.4, 25.0, 25.8, 26.6, 28.1, 28.9, 29.4, 30.1, 30.6, 31.8, 34.5, 35.3, 35.6, 36.9, a method for production thereof, use thereof as a colour developer in a heat-sensitive recording material, and a heat-sensitive recording material comprising N-(4-((4-(3-phenylureido)phenyl)sulfonyl)phenyl)benzenesulfonamide in the polymorphic form ω.sup.18.9 or in the polymorphic form α.sup.21.2.

The present invention relates to an N-(4-((4-(3-phenylureido)phenyl)sulfonyl)phenyl)benzenesulfonamide in the polymorphic form ω.sup.18.9, characterised by an x-ray powder diffractogram having the Bragg angles (2θ/CuK.sub.α) 10.9, 11.7, 14.6, 15.0, 15.8, 16.6, 17.6, 18.9, 19.4, 20.9, 21.2, 22.0, 23.3, 24.4, 24.7, 26.1, 27.4, 29.4, 34.2,

or in the polymorphic form α.sup.21.2, characterised by an x-ray powder diffractogram having the Bragg angles (2θ/CuK.sub.α) 8.7, 9.8, 10.8, 13.2, 13.9, 14.9, 15.2, 16.0, 17.4, 17.7, 18.7, 20.4, 21.2, 21.6, 22.3, 23.0, 23.3, 23.9, 24.4, 25.0, 25.8, 26.6, 28.1, 28.9, 29.4, 30.1, 30.6, 31.8, 34.5, 35.3, 35.6, 36.9, a method for production thereof, use thereof as a colour developer in a heat-sensitive recording material, and a heat-sensitive recording material comprising N-(4-((4-(3-phenylureido)phenyl)sulfonyl)phenyl)benzenesulfonamide in the polymorphic form ω.sup.18.9 or in the polymorphic form α.sup.21.2.

The present invention relates to an N-(4-((4-(3-phenylureido)phenyl)sulfonyl)phenyl)benzenesulfonamide in the polymorphic form ω.sup.18.9, characterised by an x-ray powder diffractogram having the Bragg angles (2θ/CuK.sub.α) 10.9, 11.7, 14.6, 15.0, 15.8, 16.6, 17.6, 18.9, 19.4, 20.9, 21.2, 22.0, 23.3, 24.4, 24.7, 26.1, 27.4, 29.4, 34.2, or in the polymorphic form α.sup.21.2, characterised by an x-ray powder diffractogram having the Bragg angles (2θ/CuK.sub.α) 8.7, 9.8, 10.8, 13.2, 13.9, 14.9, 15.2, 16.0, 17.4, 17.7, 18.7, 20.4, 21.2, 21.6, 22.3, 23.0, 23.3, 23.9, 24.4, 25.0, 25.8, 26.6, 28.1, 28.9, 29.4, 30.1, 30.6, 31.8, 34.5, 35.3, 35.6, 36.9, a method for production thereof, use thereof as a colour developer in a heat-sensitive recording material, and a heat-sensitive recording material comprising N-(4-((4-(3-phenylureido)phenyl)sulfonyl)phenyl)benzenesulfonamide in the polymorphic form ω.sup.18.9 or in the polymorphic form α.sup.21.2.

The present invention relates to an N-(4-((4-(3-phenylureido)phenyl)sulfonyl)phenyl)benzenesulfonamide in the polymorphic form ω.sup.18.9, characterised by an x-ray powder diffractogram having the Bragg angles (2θ/CuK.sub.α) 10.9, 11.7, 14.6, 15.0, 15.8, 16.6, 17.6, 18.9, 19.4, 20.9, 21.2, 22.0, 23.3, 24.4, 24.7, 26.1, 27.4, 29.4, 34.2, or in the polymorphic form α.sup.21.2, characterised by an x-ray powder diffractogram having the Bragg angles (2θ/CuK.sub.α) 8.7, 9.8, 10.8, 13.2, 13.9, 14.9, 15.2, 16.0, 17.4, 17.7, 18.7, 20.4, 21.2, 21.6, 22.3, 23.0, 23.3, 23.9, 24.4, 25.0, 25.8, 26.6, 28.1, 28.9, 29.4, 30.1, 30.6, 31.8, 34.5, 35.3, 35.6, 36.9, a method for production thereof, use thereof as a colour developer in a heat-sensitive recording material, and a heat-sensitive recording material comprising N-(4-((4-(3-phenylureido)phenyl)sulfonyl)phenyl)benzenesulfonamide in the polymorphic form ω.sup.18.9 or in the polymorphic form α.sup.21.2.

Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

A process for the synthesis of Dapsone and intermediates thereof are described.

A process for the synthesis of Dapsone and intermediates thereof are described.

Described are colour developers of formula (I) Ar.sup.1—SO.sub.2—NH—C.sub.6H.sub.4—SO.sub.2—C.sub.6H.sub.4—NH—CO—NH—Ar.sup.2 (I), a heat-sensitive recording material, comprising a carrier substrate and also a heat-sensitive, colour-forming layer comprising at least one colour former and at least one phenol-free colour developer, the at least one colour developer being the compound of formula (I), and a method for producing this heat-sensitive recording material.